ArticleFrontiers in cellular and infection microbiology2025
Wuling powder ameliorates diarrhea-predominant irritable bowel syndrome in mice by modulating gut mucosal microbiota and alleviating intestinal inflammation.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Electroacupuncture-mediated lncRNA TUG1 regulates the miR-127-3p/NF-κB p65 axis to inhibit IBS-D low-grade intestinal inflammation.Frontiers in immunology · 2026Article
- Development of an in situ small intestinal injection technique for targeted macromolecule delivery and in vivo functional studies in mice.Animal models and experimental medicine · 2026Article
- Commentary: Wuling powder ameliorates diarrhea-predominant irritable bowel syndrome in mice by modulating gut mucosal microbiota and alleviating intestinal inflammation.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Wuling powder has been widely used for the clinical treatment of IBS-D, but the microecological mechanism has not been found. This study aimed to investigate the regulatory effect of Wuling powder on intestinal mucosal microbiota in mice with diarrhea predominant-irritable bowel syndrome (IBS-D) by 16S rRNA high-throughput sequencing. Methods: Mice were randomly divided into normal control group (Mc), model control group (Mm), and treatment group (Mt). The IBS-D model was induced via Results: Compared with the Mc group, the Mm group presented markedly elevated serum TNF-α and IL-6 concentrations ( Conclusion: Wuling powder may inhibit the occurrence of an inflammatory response by reducing the TNF-α and IL-6 levels and increasing the MFGE8 level and may achieve the effect of treating IBS-D by regulating the composition, structure, and function of the intestinal mucosal microbiota, which provides new ideas for the clinical prevention and treatment of IBS-D via Wuling powder.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.